Closed-loop artificial pancreas: Current studies and promise for the future

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 19, Issue 2, 2012, Pages 88-92

  Weinzimer, Stuart A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

artificial pancreas; closed loop; control to range; low glucose suspend; sensor augmented pump

Indexed keywords

GLUCOSE;

ALGORITHM; ARTIFICIAL PANCREAS; BIOSENSOR; DISEASE CONTROL; FEEDBACK SYSTEM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; PATIENT SAFETY; PUMP; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ALGORITHMS; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSION PUMPS, IMPLANTABLE; INSULIN; INSULIN INFUSION SYSTEMS; MALE; PANCREAS, ARTIFICIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84858280796     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283514e6b     Document Type: Review

References (53)

1. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic retinopathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 2003; 290:2159-2167.
2. Pettiti DB, Klingensmith GJ, Bell RA, et al. Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr 2009; 155:668-672.
3. Albisser AM, Leibel BS, Ewart TG, et al. Clinical control of diabetes by the artificial pancreas. Diabetes 1974; 23:397-404.
4. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). Horm Metab Res 1977; Suppl 7:23-33
5. JDRF CGM Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359:1464-1476.
6. JDRF CGM Study Group. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care 2009; 32:1947-1953.
7. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363:311-320. The largest and longest clinical trial of sensor-augmented pump therapy to date (485 adults and children with type 1 diabtes studied for 1 year) demonstrated superiority of insulin pumps and continuous glucose monitoring to multiple daily injection regimens and routine blood glucose monitoring.
8. Slover RH, Welsh JB, Criego A, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes 2012; 13:6-11. The pediatric cohort of the STAR3 clinical trial demonstrated improvement in A1c, reduction in hyperglycemic exposure, and reduction in glycemic variability using sensor-augmented pump therapy compared with multiple daily injections with routine glucose monitoring.
9. Diabetes Research in Children Network Study Group. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children (4 to <10 year DLDs). Diabetes Care (in press).
10. Diabetes Research in Children Network Study Group. Feasibility of continuous glucose monitoring in infants and toddlers with type 1 diabetes. Diabetes 2011; 60 (Supp 1):A335.
11. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125:177-188.
12. Porter PA, Keating B, Byrne G, Jones TW. Incidence and predictive criteria of nocturnal hypoglycemia in young children with insulin-dependent diabetes mellitus. J Pediatr 1997; 130:366-372. (Pubitemid 27492679)
13. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338:1657-1662. (Pubitemid 28267910)
14. Buckingham B, Block J, Burdick J, et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther 2005; 7:440-447.
15. Buckingham B, Wilson DM, Lecher T, et al. Duration of nocturnal hypoglycemia prior to seizures. Diabetes Care 2008; 31:2110-2112.
16. Agrawal P, Welsh JB, Kannard B, et al. Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol 2011; 5:1137-1141. Data from over 900 patients over almost 50 000 patient-days of real-world use in the ambulatory setting provides compelling evidence for the safety and efficacy of sensor-augmented pump therapy with a low-glucose suspend feature: hypoglycemia was reduced without a deterioration in overall glucose control.
17. Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011; 34:2023-2025.
18. Danne T, Kordonouri O, Holder M, et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011; 13:1129-1134. A crossover study of sensor-augmented pump therapy with low-glucose suspend feature in 21 children with type 1 diabetes demonstrated efficacy (reduction of hypoglycemia episodes and time spent in hypoglycemia) and safety (no deterioration in average glucose levels) over a 6-week course.
19. Dassau E, Cameron F, Lee H, et al. Real-Time hypoglycemia prediction suite using continuous glucose monitoring: a safety net for the artificial pancreas. Diabetes Care 2010; 33:1249-1254.
20. Buckingham B, Chase HP, Dassau E, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 2010; 33:1013-1017. Using an array of five different prediction algorithms and a voting scheme to suspend basal insulin delivery when a predetermined number of algorithms predicted incipient hypoglycemia, this study demonstrated prevention of up to 75% of hypoglycemic episodes.
21. Buckingham B, Cobry E, Clinton P, et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009; 11:93-97.
22. Dassau E, Bequette BW, Buckingham BA, Doyle FJ 3rd. Detection of a meal using continuous glucose monitoring: implications for an artificial beta-cell. Diabetes Care 2008; 31:295-300. (Pubitemid 351213339)
23. Kovatchev B, Patek S, Dassau E, et al. Control to range for diabetes: functionality and modular architecture. J Diabetes Sci Technol 2009; 3:1058-1065.
24. Steil GM, Rebrin K, Janowski R, et al. Modeling beta-cell insulin secretion: implications for closed-loop glucose homeostasis. Diabetes Technol Ther 2003; 5:953-964. (Pubitemid 38009933)
25. Steil GM, Panteleon AE, Rebrin K. Closed-loop insulin delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004; 56:125-144. (Pubitemid 38114927)
26. Hovorka R, Canonico V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004; 25:905-920. (Pubitemid 39121173)
27. Magni L, Raimondo DM, Bossi L, et al. Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 2007; 1:804-812.
28. Parker RS, Doyle FJ, Peppas NA. A model-based algorithm for blood glucose control in type 1 diabetic patients. IEEE Trans Biomed Eng 1999; 46:148-157. (Pubitemid 29058920)
29. Grosman B, Dassau E, Zisser HC, et al. Zone model predictive control: a strategy to minimize hyper- and hypoglycemic events. J Diabetes Sci Technol 2010; 4:961-975.
30. Mauseth R, Wang Y, Dassau E, et al. Proposed clinical application for tuning fuzzy logic controller of artificial pancreas utilizing a personalization factor. J Diabetes Sci Technol 2010; 4:913-922.
31. Miller S, Nimri R, Atlas E, et al. Automatic learning algorithm for the MD-logic artificial pancreas system. Diabetes Technol Ther 2011; 13:983-990.
32. Gopakumaran B, Duman HM, Overholser DP, et al. A novel insulin delivery algorithm in rats with type 1 diabetes: the fading memory proportional- derivative method. Artif Organs 2005; 29:599-607. (Pubitemid 41602836)
33. El-Khatib FH, Jiang J, Damiano ER. A feasibility study of bihormonal closed-loop blood glucose control using dual subcutaneous infusion of insulin and glucagon in ambulatory diabetic swine. J Diabetes Sci Technol 2009; 3:789-803.
34. Steil GM, Rebrin K, Darwin C, et al. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006; 55:3344-3350. (Pubitemid 44923591)
35. Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery vs. semi-automated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008; 31:934-939.
36. Palerm CC. Physiologic insulin delivery with insulin feedback: a control systems perspective. Comput Methods Programs Biomed 2011; 102:130-137; Epub 2010 Aug 2.
37. Steil GM, Palerm CC, Kurtz N, et al. The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011; 96:1402-1408.
38. Ruiz JL, Sherr JL, Cengiz E, et al. Effect of insulin feedback algorithm on closed-loop blood glucose control [Abstract]. Diabetes Technol Soc 2011; A163.
39. Weinzimer SA, Sherr JL, Cengiz E, et al. Effect of adjuvant injected pramlintide on closed-loop automated insulin delivery. Diabetes 2011; 60 (Supp 1):A253.
40. Weinzimer SA, Sherr JL, Cengiz E, et al. Glucose control using closed loop insulin delivery during nights with or without antecedent afternoon exercise. Diabetes 2011; 60 (Supp 1):A42.
41. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375:743-751.
42. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011; 342:1855-1864. Two small crossover studies that showed improvements in overnight blood glucose levels (time within target and time spent hypoglycemic) with a closed-loop compared with open-loop system, after two types of mealtime challenges, one including a large meal with alcohol to simulate 'eating out'.
43. Murphy HR, Elleri D, Allen JM, et al. Closed-loop insulin delivery during pregnancycomplicated by type1 diabetes. Diabetes Care 2011; 34:406-411.
44. Murphy HR, Kumareswaran K, Elleri D, et al. Safety and efficacy of 24-h closed-loop insulin delivery in well controlled pregnant women with type 1 diabetes: a randomized crossover case series. Diabetes Care 2011; 34:2527-2529.
45. Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol 2010; 4:1374-1381. This study demonstrated that an MPC-based closed-loop system achieved superior overnight glucose control, with more time in target and less hypoglycemia, compared with an open-loop system; of note, the design and initial testing of the algorithm was accomplished entirely in silico.
46. Atlas E, Nimri R, Miller S, et al. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010; 33:1072-1076.
47. Renard E, Place J, Cantwell M, et al. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery. Diabetes Care 2010; 33:121-127.
48. El-Khatib FH, Russell SJ, Nathan DM, et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Transl Med 2010; 2:27ra27. This study in 11 adult patients with type 1 diabetes demonstrated the feasibility of a two-hormone closed-loop system, with insulin and glucagon, using two infusion pumps and two separate controller algorithms.
49. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010; 33:1282-1287.
50. Kovatchev BP, Breton M, Man CD, Cobelli C. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009; 3:44-55.
51. Dassau E, Palerm CC, Zisser H, et al. In silico evaluation platform for artificial pancreatic beta-cell development: a dynamic simulator for closed-loop control with hardware-in-the-loop. Diabetes Technol Ther 2009; 11:187-194.
52. Kanderian SS, Weinzimer SA, Voskanyan G, Steil GM. Identification of intraday metabolic profiles during closed-loop glucose control in individuals with type 1 diabetes. J Diabetes Sci Technol 2009; 3:1047-1057.
53. Wilinska ME, Chassin LJ, Acerini CL, et al. Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes. J Diabetes Sci Technol 2010; 4:132-144.